| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10070577 | European Journal of Surgical Oncology (EJSO) | 2005 | 4 Pages |
Abstract
Although there is no detrimental effect on survival after this length of follow-up, the omission of radiotherapy and tamoxifen appears to increase the probability of LR. Patients with T1 G1 N0 ER+ breast cancer treated by breast conserving surgery should be offered both radiotherapy and tamoxifen.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J. Kirkby-Bott, G. Cunnick, M.W. Kissin,